If you’ve been refreshing your ticker today looking for the MNMD stock price today, you might have noticed something weird. The name "Mind Medicine" is basically gone from the top of the charts. On January 13, 2026, the company officially rebranded to Definium Therapeutics, and the ticker flipped from MNMD to DFTX.
It’s a massive shift. Honestly, it’s more than just a name change; it’s a signal that the "shroom boom" era of speculation is dead. MindMed—now Definium—is trying to look like a grown-up pharmaceutical powerhouse. As of this weekend, January 17, 2026, the stock is sitting around $13.99 to $14.15, having flirted with a 52-week high of $15.29 just a few days ago.
The market is clearly reacting to the new "Definium" identity, but the real story isn't the logo. It's the fact that they have three massive Phase 3 readouts coming down the pipe this year.
What’s driving the MNMD stock price today?
Right now, the stock is in a "wait and see" pattern, but the volatility is real. Investors are chewing on the fact that Definium is no longer just a "psychedelic company." They are a late-stage psychiatry firm.
The price action we’re seeing today reflects a mix of optimism over their lead candidate, DT120 (formerly MM120), and the typical jitters that come with a ticker change. DT120 is an orally disintegrating tablet of lysergide D-tartrate. Basically, it’s a high-tech version of LSD designed to dissolve on the tongue.
🔗 Read more: Exchange Philippine Peso to Euro: Why Most People Lose Money (And How to Win)
The big reason the MNMD stock price today (now under DFTX) has stayed resilient above the $13 mark is the Phase 2b data that hit the Journal of the American Medical Association (JAMA) recently. That study showed a 65% clinical response rate for anxiety after just one dose. That’s wild. Most SSRIs take weeks to kick in and often come with a laundry list of side effects that make people want to quit.
The 2026 Catalyst Calendar
If you're holding these shares, your calendar should be circled in red for the next six months. The company has explicitly stated that 2026 is their "transformational year."
- Q2 2026: Topline data from the Voyage study (Phase 3 for Generalized Anxiety Disorder).
- Mid-2026: Topline data from the Emerge study (Phase 3 for Major Depressive Disorder).
- H2 2026: Topline data from the Panorama study (the second Phase 3 for GAD).
Bio-tech stocks are notoriously binary. If Voyage hits its marks in the second quarter, the current $14 price might look like a bargain. If it fails? Well, you've seen what happens to clinical-stage companies that miss their primary endpoints. It isn't pretty.
Why the rebrand to Definium Therapeutics actually matters
You might think a name change is just corporate window dressing. It's usually not. By ditching "MindMed," the company is distancing itself from the "stonk" era of 2021.
They want to be compared to companies like Sage Therapeutics or Karuna, not meme stocks. The new ticker, DFTX, is part of a broader strategy to court institutional investors who might have been allergic to the "psychedelic" label.
The company also recently pulled in about $242.8 million from an underwritten public offering. That’s a lot of cash. They’re reporting enough runway to last into 2028, which takes the immediate fear of bankruptcy off the table. Usually, when a company has that much cash, the floor for the stock price firms up because the "burn rate" is covered through the most critical clinical milestones.
The "Bears" haven't left the building
It's not all sunshine and clinical breakthroughs. Some analysts are still skeptical about the commercial side of things. Even if DT120 gets FDA approval, how do you roll out a psychedelic-derived treatment to 50 million Americans?
The logistics are a headache. You need supervised sessions. You need trained clinicians. You need insurance companies to agree that a single expensive dose is better than a cheap daily pill.
📖 Related: Carolina Comfort Air Clayton: Why Local Expertise Actually Matters for Your HVAC
There’s also the issue of dilution. That $242 million they raised didn't come out of thin air; it came from issuing new shares. Every time they do that, your slice of the pie gets a little smaller. It’s the classic biotech trap: you need money to prove the drug works, but raising that money can cap the stock's upside.
Actionable insights for the current market
If you’re looking at the MNMD stock price today and wondering what to do, you have to decide if you’re a trader or a believer.
- Watch the $13.50 Support Level: Historically, the stock has found buyers around this area. If it dips below $13 on high volume without news, that’s a red flag.
- Monitor the Ticker Transition: Ensure your brokerage has updated your holdings to DFTX. Some older platforms can be slow with name changes, which can temporarily affect your ability to trade or set stop-losses.
- Risk Management: This is still a clinical-stage biotech. Never put "rent money" into a stock that is 100% dependent on an FDA readout. The "Emerge" study for depression was actually accelerated because enrollment went faster than expected, which is a good sign, but doesn't guarantee a "win."
- Keep an eye on the Peers: Watch how Compass Pathways (CMPS) and Cybin (CYBN) are trading. Often, this whole sector moves as one big "psychedelic" block, regardless of individual company news.
Ultimately, the stock is currently priced for "perfection" in its upcoming trials. If you're looking for a entry point, any significant pull-back toward the $11 or $12 range might be viewed as a buying opportunity by those who trust the Phase 2 data. Just keep your eyes on the Q2 2026 "Voyage" results—that is the moment that will define the stock's trajectory for the rest of the decade.